Interestingly, GSDME‐deficient melanoma represents defective HMGB1 release, the reduced infiltration of tumor‐associated T cells and activated DCs in response to BRAFi + MEKi treatment, and the more frequent tumor regrowth after drug removal. The gene discussed is HMGB1; the disease is neoplasm.